#ITI#Latency and tumorigenesis in Marek's disease#FTI#
#IRE#Despite the remarkable progress in our understanding of Marek's disease (MD) and the causative Marek's disease virus (MDV) biology, a number of major features of this complex viral disease remain unknown. Significant information on critical aspects of virus latency in lymphoid cells, and the virus-host interaction in MDV-induced lymphoma, remains to be identified. Moreover, the nature of the unique milieu of the feather follicle epithelial cell that allows cytolytic infection to continue, despite maintaining the latent infection in the lymphoid cells, is not fully understood. Although there has been significant progress in our understanding of the functions of a number of viral genes in the pathogenesis of the disease, the characteristics of the latent infection, how it differs from tumor phase, and whether latency is a prerequisite for the tumor phase are all important questions still to be answered. Reticuloendotheliosis virus-transformed cell lines have been shown to support MDV latency in a manner almost identical to that seen in MDV-transformed cell lines. There are increasing data on the role of epigenetic regulation, including DNA methylation and histone modifications, in maintaining viral latency. Onset of MD tumor is relatively rapid, and recent studies based on chromosomal integration and T-cell repertoire analysis demonstrated the clonal nature of MD lymphomas. Among the viral determinants of oncogenicity, the basic leucine zipper protein Meq is considered to be the most important and the most extensively studied. Deleting the Meq proteins or abolishing some of the important interactions does affect the oncogenicity of the virus. In addition, the noncoding sequences in the viral genome, such as the viral telomerase RNA and the virus-encoded microRNAs, also have significant influence on MDV-encoded oncogenesis. Â© American Association of Avian Pathologists.#FRE#
#IPC#BAC; ICP4; Latency; MDV; Meq; microRNA; Oncogenesis; pp38; Telomerase; Telomeric RNA; Tumorigenesis#FPC#
#IRF#Afonso C.L., Tulman E.R., Lu Z., Zsak L., Rock D.L., Kutish G.F., The genome of turkey herpesvirus, J. Virol., 75, pp. 971-978, (2001); 
Ajithdoss D.K., Reddy S.M., Suchodolski P.F., Lee L.F., Kung H.J., Lupiani B., In vitro characterization of the Meq proteins of Marek's disease virus vaccine strain CVI988, Virus Res., 142, pp. 57-67, (2009); 
Arumugaswami V., Kumar P.M., Konjufca V., Dienglewicz R.L., Reddy S.M., Parcells M.S., Latency of Marek's disease virus (MDV) in a reticuloendotheliosis virus-transformed T-cell line I: Uptake and structure of the latent MDV genome, Avian Dis., 53, pp. 149-155, (2009); 
Arumugaswami V., Kumar P.M., Konjufca V., Dienglewicz R.L., Reddy S.M., Parcells M.S., Latency of Marek's disease virus (MDV) in a reticuloendotheliosis virus-transformed T-cell line II: Expression of the latent MDV genome, Avian Dis., 53, pp. 156-165, (2009); 
Baigent S., Davison F., Marek's disease virus: Biology and life cycle, Marek's Disease, An Evolving Problem, pp. 62-77, (2004); 
Biggs P.M., Nair V., The long view: 40 years of Marek's disease research and avian pathology, Avian Pathol., 41, pp. 3-9, (2012); 
Bradley G., Hayashi M., Lancz G., Tanaka A., Nonoyama M., Structure of the Marek's disease virus BamHI-H gene family: Genes of putative importance for tumor induction, J. Virol., 63, pp. 2534-2542, (1989); 
Bradley G., Lancz G., Tanaka A., Nonoyama M., Loss of Marek's disease virus tumorigenicity is associated with truncation of RNAs transcribed within BamHI-H, J. Virol., 63, pp. 4129-4135, (1989); 
Brown A.C., Baigent S.J., Smith L.P., Chattoo J.P., Petherbridge L.J., Hawes P., Allday M.J., Nair V., Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus, PNAS, 103, pp. 1687-1692, (2006); 
Brown A.C., Smith L.P., Kgosana L., Baigent S.J., Nair V., Allday M.J., Homodimerization of the Meq viral oncoprotein is necessary for induction of T-cell lymphoma by Marek's disease virus, J. Virol., 83, pp. 11142-11151, (2009); 
Brown A.C., Nair V., Allday M.J., Epigenetic regulation of the latency-associated region of Marek's disease virus in tumor-derived T-cell lines and primary lymphoma, J. Virol., 86, pp. 1683-1695, (2012); 
Burnside J., Bernberg E., Anderson A., Lu C., Meyers B.C., Green P.J., Jain N., Isaacs G., Morgan R.W., Marek's disease virus encodes microRNAs that map to Meq and the latency-associated transcript, J. Virol., 80, pp. 8778-8786, (2006); 
Calnek B.W., Marek's disease: A model for herpesvirus oncology, CRC Crit. Rev. Microbiol., 12, pp. 293-320, (1986); 
Cantello J.L., Anderson A.S., Morgan R.W., Identification of latency-associated transcripts that map antisense to the ICP4 homolog gene of Marek's disease virus, J. Virol., 68, pp. 6280-6290, (1994); 
Cantello J.L., Parcells M.S., Anderson A.S., Morgan R.W., Marek's disease virus latency-associated transcripts belong to a family of spliced RNAs that are antisense to the ICP4 homolog gene, J. Virol., 71, pp. 1353-1361, (1997); 
Chbab N., Egerer A., Veiga I., Jarosinski K.W., Osterrieder N., Viral control of vTR expression is critical for efficient formation and dissemination of lymphoma induced by Marek's disease virus (MDV), Vet. Res., 41, (2010); 
Chinnadurai G., CtBP an unconventional transcriptional corepressor in development and oncogenesis, Mol. Cell, 9, pp. 213-224, (2002); 
Cortes P.L., Cardona C.J., Pathogenesis of a Marek's disease virus mutant lacking vIL-8 in resistant and susceptible chickens, Avian Dis., 48, pp. 50-60, (2004); 
Delecluse H.-J., Hammerschmidt W., Status of Marek's disease virus in established lymphoma cell lines: Herpesvirus integration is common, J. Virol., 67, pp. 82-92, (1993); 
Delecluse H.-J., Schuller S., Hammerschmidt W., Latent Marek's disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells, Eur. Mol. Biol. Organ. J., 12, pp. 3277-3286, (1993); 
Deng X., Li X., Shen Y., Qiu Y., Shi Z., Shao D., Jin Y., Chen H., Ding C., Li L., Chen P., Ma Z., The Meq oncoprotein of Marek's disease virus interacts with p53 and inhibits its transcriptional and apoptotic activities, Virol. J., 7, (2010); 
Dunn J.R., Silva R.F., Ability of MEQ-deleted MDV vaccine candidates to adversely affect lymphoid organs and chicken weight gain, Avian Dis., 56, pp. 494-500, (2012); 
Engel A.T., Selvaraj R.K., Kamil J.P., Osterrieder N., Kaufer B.B., Marek's disease viral interleukin-8 promotes lymphoma formation through targeted recruitment of B cells and CD4+ CD25+ T cells, J. Virol., 86, pp. 8536-8545, (2012); 
Fragnet L., Blasco M.A., Klapper W., Rasschaert D., The RNA subunit of telomerase is encoded by Marek's disease virus, J. Virol., 77, pp. 5985-5996, (2003); 
Fragnet L., Kut E., Rasschaert D., Comparative functional study of the viral telomerase RNA based on natural mutations, J. Biol. Chem., 280, pp. 23502-23515, (2005); 
Hickabottom M., Parker G.A., Freemont P., Crook T., Allday M.J., Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP), J. Biol. Chem., 277, pp. 47197-47204, (2002); 
Hong Y., Coussens P.M., Identification of an immediate-early gene in the Marek's disease virus long internal repeat region which encodes a unique 14-kilodalton polypeptide, J. Virol., 68, pp. 3593-3603, (1994); 
Hong Y., Frame M., Coussens P.M., A 14-kDa immediate-early phosphoprotein is specifically expressed in cells infected with oncogenic Marek's disease virus strains and their attenuated derivatives, Virology, 206, pp. 695-700, (1995); 
Jarosinski K., Kattenhorn L., Kaufer B., Ploegh H., Osterrieder N., A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation, Proc. Natl. Acad. Sci. U.S.A., 104, pp. 20025-20030; 
Kaufer B.B., Trapp S., Jarosinski K.W., Osterrieder N., Herpesvirus telomerase RNA(vTR) dependent lymphoma formation does not require interaction of vTR with telomerase reverse transcriptase (TERT), PLoS Pathog, 6, (2010); 
Kaufer B.B., Arndt S., Trapp S., Osterrieder N., Jarosinski K.W., Herpesvirus telomerase RNA (vTR) with a mutated template sequence abrogates herpesvirus-induced lymphomagenesis, PLoS Pathog, 7, (2007); 
Kung H.J., Xia L., Brunovskis P., Li D., Liu J.L., Lee L.F., Meq: An MDV-specific bZIP transactivator with transforming properties, Curr. Top. Microbiol. Immunol., 255, pp. 245-260, (2001); 
Lee L.F., Wu P., Sui D., Ren D., Kamil J., Kung H.J., Witter R.L., The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus, Proc. Natl. Acad. Sci. U.S.A., 97, pp. 6091-6096, (2000); 
Lee L.F., Kreager K.S., Arango J., Paraguassu A., Beckman B., Zhang H., Fadly A., Lupiani B., Reddy S.M., Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens, Vaccine, 28, pp. 1294-1299, (2010); 
Levy A.M., Gilad O., Xia L., Izumiya Y., Choi J., Tsalenko A., Yakhini Z., Witter R., Lee L., Cardona C.J., Kung H.J., Marek's disease virus Meq transforms chicken cells via the v-Jun transcriptional cascade: A converging transforming pathway for avian oncoviruses, Proc. Natl. Acad. Sci. U.S.A., 102, pp. 14831-14836, (2005); 
Li D.-S., Pastorek J., Zelnik V., Smith G.D., Ross L.J.N., Identification of novel transcripts complementary to the Marek's disease virus homologue of the ICP4 gene of herpes simplex virus, J. Gen. Virol., 75, pp. 1713-1722, (1994); 
Luo Z., Zhang L., Li Z., Li X., Li G., Yu H., Jiang C., Dai Y., Guo X., Xiang J., Li G., An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma, BMC Med. Genomics, 5, (2012); 
Lupiani B., Lee L.F., Reddy S.M., Protein-coding content of the sequence of Marek's disease virus serotype 1, Curr. Top. Microbiol. Immunol., 255, pp. 159-190, (2001); 
Lupiani B., Lee L.F., Cui X., Gimeno I., Anderson A., Silva R.F., Witter R.L., Kung H.J., Reddy S.M., Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication, Proc. Natl. Acad. Sci. U.S.A., 101, pp. 11815-11820, (2004); 
McKie E.A., Ubukata E., Hasegawa S., Zhang S., Nonoyama M., Tanaka A., The transcripts from the sequences flanking the short component of Marek's disease virus during latent infection form a unique family of 39-coterminal RNAs, J. Virol., 69, pp. 1310-1314, (1995); 
Morissette G., Flamand L., Herpesviruses and chromosomal integration, J. Virol., 84, pp. 12100-12109, (2010); 
Mwangi W.N., Beal R.K., Powers C., Wu X., Humphrey T., Watson M., Bailey M., Friedman A., Smith A.L., Regional and global changes in TCRalphabeta T cell repertoires in the gut are dependent upon the complexity of the enteric microflora, Dev. Comp. Immunol., 34, pp. 406-417, (2010); 
Mwangi W.N., Smith L.P., Baigent S.J., Beal R.K., Nair V., Smith A.L., Clonal structure of rapid-onset MDV-driven CD4+lymphomas and responding CD8+ T cells, PLoS Pathog, 7, (2011); 
Nair V., Kung H.J., Marek's disease virus oncogenicity: Molecular mechanisms, Marek's Disease, An Evolving Problem, pp. 32-48, (2004); 
Niikura M., Dodgson J.B., Cheng H.H., Stability of Marek's disease virus 132-bp repeats during serial in vitro passages, Arch. Virol, (2006); 
Osterrieder N., Kamil J.P., Schumacher D., Tischer B.K., Trapp S., Marek's disease virus: From miasma to model, Nat. Rev. Micro., 4, pp. 283-294, (2006); 
Parcells M., Burnside J., Morgan R., Marek's disease virusinduced T-cell lymphomas Cancer associated viruses-current research, Science+Business Media, pp. 307-335, (2012); 
Parcells M.S., Lin S.F., Dienglewicz R.L., Majerciak V., Robinson D.R., Chen H.C., Wu Z., Dubyak G.R., Brunovskis P., Hunt H.D., Lee L.F., Kung H.J., Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): Characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV, J. Virol., 75, pp. 5159-5173, (2001); 
Petherbridge L., Brown A.C., Baigent S.J., Howes K., Sacco M.A., Osterrieder N., Nair V.K., Oncogenicity of virulent Marek's disease virus cloned as bacterial artificial chromosomes, J. Virol., 78, pp. 13376-13380, (2004); 
Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., John B., Enright A.J., Marks D., Sander C., Tuschl T., Identification of virus-encoded microRNAs, Science, 304, pp. 734-736, (2004); 
Pratt W.D., Morgan R.W., Schat K.A., Characterization of reticuloendotheliosis virus-transformed avian T-lymphoblastoid cell lines infected with Marek's disease virus, J. Virol., 66, pp. 7239-7244, (1992); 
Reddy S.M., Lupiani B., Gimeno I.M., Silva R.F., Lee L.F., Witter R.L., Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: Use of a pp38 mutant to validate the technology for the study of gene function, Proc. Natl. Acad. Sci. U.S.A., 99, pp. 7054-7059, (2002); 
Reinke A.W., Grigoryan G., Keating A.E., Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and KbZIP using coiled-coil arrays, Biochemistry, 49, pp. 1985-1997, (2010); 
Robinson C.M., Hunt H.D., Cheng H.H., Delany M.E., Chromosomal integration of an avian oncogenic herpesvirus reveals telomeric preferences and evidence for lymphoma clonality, Herpesviridae, 1, (2010); 
Ross N., Binns M.M., Sanderson M.J., Schat K.A., Alterations in DNA sequence and RNA transcription of the Bam HI-H fragment accompany attenuation of oncogenic Marek's disease herpesvirus, Virus Genes, 7, pp. 33-51, (1993); 
Ross N., O'Sullivan G., Rothwell C., Smith G., Burgess S.C., Rennie M., Lee L.F., Davison T.F., Marek's disease virus EcoRI-Q gene (Meq) and a small RNA antisense to ICP4 are abundantly expressed in CD4+ cells and cells carrying a novel lymphoid marker, AV37, in Marek's disease lymphomas, J. Gen. Virol., 78, PART 9, pp. 2191-2198, (1997); 
Ross N.L., T-cell transformation by Marek's disease virus, Trends Microbiol., 7, pp. 22-29, (1999); 
Schat K.A., Buckmaster A., Ross L.J.N., Partial transcription map of Marek's disease herpesvirus in lytically infected cells and lymphoblastoid cell lines, Int. J. Cancer, 44, pp. 101-109, (1989); 
Schumacher D., Tischer B.K., Fuchs W., Osterrieder N., Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant, J. Virol., 74, pp. 11088-11098, (2000); 
Shkreli M., Dambrine G., Soubieux D., Kut E., Rasschaert D., Involvement of the oncoprotein c-Myc in viral telomerase RNA gene regulation during Marek's disease virus-induced lymphomagenesis, J. Virol., 81, pp. 4848-4857, (2007); 
Silva R.F., Reddy S.M., Lupiani B., Expansion of a unique region in the Marek's disease virus genome occurs concomitantly with attenuation but is not sufficient to cause attenuation, J. Virol., 78, pp. 733-740, (2004); 
Silva R.F., Dunn J.R., Cheng H.H., Niikura M., A MEQdeleted Marek's disease virus cloned as a bacterial artificial chromosome is a highly efficacious vaccine, Avian Dis., 54, pp. 862-869, (2010); 
Skalska L., White R.E., Franz M., Ruhmann M., Allday M.J., Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP, PLoS Pathog, 6, (2010); 
Spatz S.J., Petherbridge L., Zhao Y., Nair V., Comparative fulllength sequence analysis of oncogenic and vaccine (Rispens) strains of Marek's disease virus, J. Gen. Virol., 88, pp. 1080-1096, (2007); 
Spatz S.J., Schat K.A., Comparative genomic sequence analysis of the Marek's disease vaccine strain SB-1, Virus Genes, 42, pp. 331-338, (2011); 
Suchodolski P.F., Izumiya Y., Lupiani B., Ajithdoss D.K., Gilad O., Lee L.F., Kung H.J., Reddy S.M., Homodimerization of Marek's disease virus-encoded Meq protein is not sufficient for transformation of lymphocytes in chickens, J. Virol., 83, pp. 859-869, (2009); 
Suchodolski P.F., Izumiya Y., Lupiani B., Ajithdoss D.K., Lee L.F., Kung H.J., Reddy S.M., Both homo and heterodimers of Marek's disease virus encoded Meq protein contribute to transformation of lymphocytes in chickens, Virology, 399, pp. 312-321, (2010); 
Sugaya K., Bradley G., Nonoyama M., Tanaka A., Latent transcripts of Marek's disease virus are clustered in the short and long repeat regions, J. Virol., 64, pp. 5773-5782, (1990); 
Tahiri-Alaoui A., Matsuda D., Xu H., Panagiotis P., Burman L., Lambeth L.S., Petherbridge L., James W., Mauro V., Nair V., The 59 leader of the mRNA encoding the Marek's disease virus serotype 1 pp14 protein contains an intronic internal ribosome entry site with allosteric properties, J. Virol., 83, pp. 12769-12778, (2009); 
Tahiri-Alaoui A., Smith L.P., Baigent S., Kgosana L., Petherbridge L.J., Lambeth L.S., James W., Nair V., Identification of an intercistronic internal ribosome entry site in a Marek's disease virus immediate-early gene, J. Virol., 83, pp. 5846-5853, (2009); 
Touitou R., Hickabottom M., Parker G., Crook T., Allday M.J., Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C, J. Virol., 75, pp. 7749-7755, (2001); 
Trapp S., Parcells M.S., Kamil J.P., Schumacher D., Tischer B.K., Kumar P.M., Nair V.K., Osterrieder N., A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis, J. Exp. Med., 203, pp. 1307-1317, (2006); 
Tulman E.R., Afonso C.L., Lu Z., Zsak L., Rock D.L., Kutish G.F., The genome of a very virulent Marek's disease virus, J. Virol., 74, pp. 7980-7988, (2000); 
Xu S., Xue C., Li J., Bi Y., Cao Y., Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth factor beta signal pathway, J. Virol., 85, pp. 276-285, (2011); 
Yamaguchi T., Kaplan S.L., Wakenell P., Schat K.A., Transactivation of latent Marek's disease herpesvirus genes in QT35, a quail fibroblast cell line, by herpesvirus of turkeys, J. Virol., 74, pp. 10176-10186, (2000); 
Yao Y., Zhao Y., Xu H., Smith L.P., Lawrie C.H., Sewer A., Zavolan M., Nair V., Marek's disease virus type 2 (MDV-2)-encoded microRNAs show no sequence conservation with those encoded by MDV-1, J. Virol., 81, pp. 7164-7170, (2007); 
Yao Y., Zhao Y., Smith L.P., Lawrie C.H., Saunders N.J., Watson M., Nair V., Differential expression of microRNAs in Marek's disease virus-transformed T-lymphoma cell lines, J. Gen. Virol., 90, pp. 1551-1559, (2009); 
Zhao Y., Kurian D., Xu H., Petherbridge L., Smith L.P., Hunt L., Nair V., Interaction of Marek's disease virus oncoprotein Meq with heat-shock protein 70 in lymphoid tumour cells, J. Gen. Virol., 90, pp. 2201-2208, (2009); 
Zhao Y., Yao Y., Xu H., Lambeth L., Smith L.P., Kgosana L., Wang X., Nair V., A functional microRNA-155 ortholog encoded by the oncogenic Marek's disease virus, J. Virol., 83, pp. 489-492, (2009); 
Zhao Y., Xu H., Yao Y., Smith L.P., Kgosana L., Green J., Petherbridge L., Baigent S.J., Nair V., Critical role of the virus-encoded microRNA-155 ortholog in the induction of Marek's disease lymphomas, PLoS Pathog, 7, (2011)#FRF#
